In vivo anti-inflammatory activity of M116, one extract obtained from the marine bacterium Bacillus amyloliquefaciens

• Published in: Journal of pharmacy & pharmacognosy research 2023-07, Vol.11 (4), p.651-661
• Main Authors: Hernández-Balmaseda, Ivones, López Lezcano, Fernando, Cuellar Duarte, Cindel, Garrido-Suárez, Bárbara B., Ortiz Guilarte, Eudalys, Fernández Pérez, Miguel D., Rodeiro Guerra, Idania
• Format: Article
• Language: English
• Subjects: anti-inflammatory activity; bacillus amyloliquefaciens; inflammation; marine microorganisms
• ISSN: 0719-4250; 0719-4250
• DOI: 10.56499/jppres23.1619_11.4.651

Context: Marine organisms are sources of compounds with anti-inflammatory activity, many of them derived from the secondary metabolites produced by microorganisms. Aims: To evaluate the possible anti-inflammatory effect of M116, an extract obtained by fermentation from the CBM-116 strain of the marine bacterium Bacillus amyloliquefaciens, which was isolated from sediments of the southern coast of the Cuban shelf. Methods: The oral single and repeated different doses of the CBM-116 were evaluated for their ability to ameliorate edema using two in vivo experimental inflammation models: croton oil-induced atrial acute edema and cotton pellets-induced chronic granuloma, both in male Balb/c mice. The systemic production of redox biomarkers after repeated doses in the chronic inflammation model was also tested. Results: A single application of M116 (50-200 mg/kg, 10 mL/kg, p.o.) decreases croton oil-induced acute inflammation in a dose-dependent manner. Single and repeated doses of extract (100-400 mg/kg, p.o.) also were able to inhibit chronic inflammation during both, transudative and proliferative phases of the inflammatory process. This effect was associated with the systemic reduction of oxidative stress. Conclusions: M116 showed anti-inflammatory activity in the context of acute and chronic inflammation associated with its antioxidant mechanisms, which suggest the potential of the marine bacterium Bacillus amyloliquefaciens as a source of new products with biomedical application.